ArticleJournal of managed care & specialty pharmacy2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Thomas E Delea et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this paperpooled ittrialcites it